Clinical trial
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT07485010 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
- Lead sponsor
- The University of Queensland
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- April 30, 2027
- Completion date
- July 31, 2031
- Enrollment
- 300 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
mycobacterium abscessus infection, mycobacterium abscessus pulmonary disease, non-tuberculous mycobacteria pulmonary disease, non-tuberculous mycobacterial (ntm) infections